2022 Aug;24(8):1553-1564
Department of Veterans Affairs has launched a new clinical trial to determine whether GLP-1 medications, the fast-growing class of drugs used to treat diabetes and obesity, can also help veterans reduce or stop drinking
And finally, it's a waste of valuable resources
Glucagon-like peptide-1 receptor agonist, semaglutide attenuates chronic liver disease-induced skeletal muscle atrophy in diabetic mice
When Semaglutide is administered, it activates GLP-1 receptors in the body, leading to several key mechanisms that contribute to weight loss: Appetite Suppression: Semaglutide reduces feelings of hunger, making it easier for individuals to consume fewer calories and control their food intake
Ideally, wed have the exact figures in the number of heart attacks or strokes between the semaglutide group and the placebo group to determine whats known as the absolute risk